



41

1615  
\$1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Stamm et al**

Application No. **09/899,026**

Group Art Unit: **1615**

Filed: **July 6, 2001**

Examiner: **Sheikh**

For: **FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND METHOD FOR PREPARING IT**

Attorney Docket No: 107664.115US3

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Transmittal Letter**

The following documents are submitted herewith for appropriate action by the US Patent Office:

1. Response and Amendment under 37 CFR § 1.111.
2. Terminal Disclaimer.
3. Information Disclosure Statement, PTO-1449 Form, and copy of cited references.

The Commissioner is authorized to charge the fee of **\$308** (which includes \$180 for the Information Disclosure Statement; \$110 for the Terminal Disclaimer; and \$18 for the Excess Claim Fee) to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219.

Respectfully submitted,

Edward D. Grieff  
Registration No. 38,898

Date: March 30, 2004  
HALE AND DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: (202) 942-8400